Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: news events 2018 advances inflammatory bowel diseases conference
… models for biologic therapies in eosinophilic-associated diseases. We performed a targeted search of the Embase … cost-effectiveness of biologics in eosinophilic-associated diseases. Poster presented at the ISPOR Europe 2023; November …
… on Drug Therapy in HIV Infection; the European AIDS conference; Intersciences Conference on Antimicrobial Agents and Chemotherapy (ICAAC); …
Christopher N. Graham Health Economics Psychiatry Ophthalmology Oncology Cardiovascular Headquarters - Research Triangle Park, North Carolina, USA MS, Clinical Epidemiology & Health Services Research Wake Forest University, Winston-Salem, NC BS, Biology …
… RTI Health Solutions Jennifer attended the AMCP 2024 conference and brings back these insights. The Academy of …
Assess Long-Term Treatment Effects with Pooled Database Analysis Share on: November 27, 2023 For drug and biotech developers, understanding long-term treatment effects is an important part of evaluating the benefit-risk balance of their products. …
Identifying Psychosis in Patients with Dementia: Not a Hallucination or Delusion, the Challenge Really Exists Share on: August 22, 2019 Identifying Psychosis in Patients with Dementia: Not a Hallucination or Delusion, the Challenge Really Exists Joan …
… and gain market access for products to treat ocular diseases and complications arising from treatment of ocular diseases. Recent projects have included: Database analyses …
… and gain market access for products to treat rheumatology diseases and complications arising from treatment of rheumatology diseases. Recent projects have included: Benefit-risk …
Biostatistics Data Analysis and Visualization Can Help Strengthen Your Pharma or Medical Technology Product Development The value of your data may be greater than you think. Unexplored trial or observational data may contain a goldmine of information to …
… Markets HTA and Reimbursement Considerations for Rare Diseases in European Markets: What Are the Implications for … More companies are developing orphan drugs for rare diseases. But the available evidence to support orphan drug … countries have introduced special considerations for rare diseases, but evidence guidelines for orphan and nonorphan …